PGD2 Formation in Vascular Injury

• Status: Terminated
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the biosynthesis of PGD2 during percutaneous transluminal coronary angioplasty (PTCA) procedure.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Patients with existing CAD admitted for elective PTCA:

1. Treated with any dose of aspirin daily for at least 5 days, with special interest in those treated with 81 mg aspirin daily or

2. Treated with an alternative antiplatelet therapy, such as clopidogrel, due to aspirin hypersensitivity or PMDs preference or

3. No aspirin therapy at all

• Patients presenting to the ER with Acute Coronary Syndrome(ACS)who will have a PTCA

• Patients with stable angina or positive stress tests scheduled for a cardiac catheterization

Exclusion Criteria:

• History of unstable diabetes (hgb A1c>8 or FBS> 200)

• Uncontrolled hypertension (SBP > 180, DBP >100)

• History of an acute confounding disease as judged on clinical screen that according to the investigator may interfere with interpretation of the study results, or compromise the safety of a potential subject.

• Patients who have taken NSAIDS or COX-2 inhibitors other than aspirin, for at least 10 days prior to PTCA